<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Zouache MA</submitter><funding>U.S. Department of Health &amp;amp; Human Services | NIH | National Eye Institute</funding><funding>NEI NIH HHS</funding><funding>Research to Prevent Blindness</funding><funding>Additional funding from philanthropic donations to the Steele Center for Translational Medicine, John A. Moran Eye Center, University of Utah.</funding><pagination>443</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC10781981</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>15(1)</volume><pubmed_abstract>Dysregulation of the alternative pathway (AP) of the complement system is a significant contributor to age-related macular degeneration (AMD), a primary cause of irreversible vision loss worldwide. Here, we assess the contribution of the liver-produced complement factor H-related 4 protein (FHR-4) to AMD initiation and course of progression. We show that FHR-4 variation in plasma and at the primary location of AMD-associated pathology, the retinal pigment epithelium/Bruch's membrane/choroid interface, is entirely explained by three independent quantitative trait loci (QTL). Using two distinct cohorts composed of a combined 14,965 controls and 20,741 cases, we ascertain that independent QTLs for FHR-4 are distinct from variants causally associated with AMD, and that FHR-4 variation is not i</pubmed_abstract><journal>Nature communications</journal><pubmed_title>Levels of complement factor H-related 4 protein do not influence susceptibility to age-related macular degeneration or its course of progression.</pubmed_title><pmcid>PMC10781981</pmcid><funding_grant_id>Unrestricted Grant to the Department of Ophthalmology &amp;amp; Visual Sciences, University of Utah.</funding_grant_id><funding_grant_id>R24 EY017404</funding_grant_id><funding_grant_id>R24EY017404</funding_grant_id><pubmed_authors>Fleckenstein M</pubmed_authors><pubmed_authors>Liu J</pubmed_authors><pubmed_authors>Schmitz-Valckenberg S</pubmed_authors><pubmed_authors>Hageman GS</pubmed_authors><pubmed_authors>Williams BL</pubmed_authors><pubmed_authors>Seager NA</pubmed_authors><pubmed_authors>Corsetti T</pubmed_authors><pubmed_authors>Thomas J</pubmed_authors><pubmed_authors>Zouache MA</pubmed_authors><pubmed_authors>Anstadt RA</pubmed_authors><pubmed_authors>Hageman JL</pubmed_authors><pubmed_authors>Hubbard WC</pubmed_authors><pubmed_authors>Richards BT</pubmed_authors><pubmed_authors>Pappas CM</pubmed_authors><pubmed_authors>Matthews S</pubmed_authors></additional><is_claimable>false</is_claimable><name>Levels of complement factor H-related 4 protein do not influence susceptibility to age-related macular degeneration or its course of progression.</name><description>Dysregulation of the alternative pathway (AP) of the complement system is a significant contributor to age-related macular degeneration (AMD), a primary cause of irreversible vision loss worldwide. Here, we assess the contribution of the liver-produced complement factor H-related 4 protein (FHR-4) to AMD initiation and course of progression. We show that FHR-4 variation in plasma and at the primary location of AMD-associated pathology, the retinal pigment epithelium/Bruch's membrane/choroid interface, is entirely explained by three independent quantitative trait loci (QTL). Using two distinct cohorts composed of a combined 14,965 controls and 20,741 cases, we ascertain that independent QTLs for FHR-4 are distinct from variants causally associated with AMD, and that FHR-4 variation is not i</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 Jan</publication><modification>2026-06-02T11:29:43.467Z</modification><creation>2024-11-09T13:40:26.526Z</creation></dates><accession>S-EPMC10781981</accession><cross_references><pubmed>38200010</pubmed><doi>10.1038/s41467-023-44605-0</doi></cross_references></HashMap>